FULCRUM THERAPEUTICS, INC. Net Income (Loss) Attributable to Parent, Diluted
FULCRUM THERAPEUTICS, INC. (FULC) reported Net Income (Loss) Attributable to Parent, Diluted of -$19.59 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-29.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2025-10-29
- FULCRUM THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-09-30 was -$19.59M.
- FULCRUM THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-06-30 was -$17.30M, a 131.22% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2024-09-30 was -$21.70M.
- FULCRUM THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2024-06-30 was $55.41M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month |
|---|---|---|---|
| 2025-09-30 | -$19.59M 10-Q · filed 2025-10-29 | -$36.89M derived: sum of 2 quarters · filed 2025-10-29 | -$54.55M 10-Q · filed 2025-10-29 |
| 2025-06-30 | -$17.30M 10-Q · filed 2025-07-29 | -$34.95M 10-Q · filed 2025-07-29 | |
| 2024-09-30 | -$21.70M 10-Q · filed 2025-10-29 | $33.71M derived: sum of 2 quarters · filed 2025-10-29 | $6.84M 10-Q · filed 2025-10-29 |
| 2024-06-30 | $55.41M 10-Q · filed 2025-07-29 | $28.54M 10-Q · filed 2025-07-29 | |
| 2023-09-30 | -$24.02M 10-Q · filed 2024-11-13 | -$47.80M derived: sum of 2 quarters · filed 2024-11-13 | -$72.58M 10-Q · filed 2024-11-13 |
| 2023-06-30 | -$23.78M 10-Q · filed 2024-07-31 | -$48.56M 10-Q · filed 2024-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |